Tenofovir Disoproxil and Ledipasvir/Sofosbuvir Interaction

Understanding the Tenofovir Disoproxil and Ledipasvir/Sofosbuvir Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Tenofovir Disoproxil belongs to the Nucleotide Reverse Transcriptase Inhibitor class and Ledipasvir/Sofosbuvir belongs to the NS5A/NS5B Inhibitor (HCV) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Taking these drugs together can increase the amount of tenofovir in your blood. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Tenofovir Disoproxil has 14 total documented interactions on file in this dataset, and Ledipasvir/Sofosbuvir has 22. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should monitor you closely for any side effects caused by tenofovir while you are taking both medications. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Tenofovir Disoproxil or Ledipasvir/Sofosbuvir based on a web page, speak with your prescriber or pharmacist before making any change.